Updates from Syncona and our portfolio companies
Experienced Non-Executive Director with strategic and operational leadership in global companies
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, announces the appointment of Kenneth Galbraith as Executive in Residence. Ken brings over 30 years’ experience in biotechnology and venture capital and will work alongside the Syncona Investment Management Limited team to support portfolio companies as they scale and develop.
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for AUTO1, the company’s CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory (r/r) adult B-Acute Lymphocytic Leukemia (ALL).
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will attend the following virtual investor conferences:
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the pricing of its initial public offering in the United States of 9,750,000 American Depositary Shares (“ADSs”) representing 9,750,000 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of $175.5 million.
Autolus to expand on existing operations in the UK for commercial supply of AUTO1 resulting in a less capital-intensive commercial infrastructure strategy. Mutual agreement to terminate lease for the manufacturing and office facility at 9950 Medical Center Drive, Rockville, MD, resulting in a cash payment to Autolus
ANV419 is a powerful and selective interleukin-2 (IL-2) agonist targeting cancer
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced that Marita James, CPA, has been appointed as the company’s Chief Financial Officer.